Journal: Cancers

Article Title: MiRNAs in Alcohol-Related Liver Diseases and Hepatocellular Carcinoma: A Step toward New Therapeutic Approaches?

doi: 10.3390/cancers15235557

Figure Lengend Snippet: Summary of deregulated miRNAs in ALD and cited in this review.

Article Snippet: MiR-10a , PI3K/AKT/mTOR , HCC patients, human HCC cell lines (Huh7, HepG2, and PLC) , Cell proliferation inhibition chemosensibility , Musashi 1 (MSI1) , [ ] .

Techniques: Expressing, Transformation Assay, Activation Assay, Migration

Journal: Cancers

Article Title: MiRNAs in Alcohol-Related Liver Diseases and Hepatocellular Carcinoma: A Step toward New Therapeutic Approaches?

doi: 10.3390/cancers15235557

Figure Lengend Snippet: ( A ) A transcriptomic dataset (GSE59492 from Gene Expression Omnibus Database) was used to analyze deregulated miRNAs between control and alcohol-related cirrhotic livers ( B ) A literature-based screening was used to classify them in oncomiRs or tumor suppressor miRNAs (miRsupressors). ( C ) Among deregulated miRNAs, some have unknown functions in HCC. ( D ) Overexpression of some of these microRNAs, such as miR-3622a, can be observed in HCC tumors (data retrieved from miRTV database in July 2023). ( E ) The same transcriptomic dataset (GSE59492) was used to compare deregulated miRNAs in alcohol-related cirrhosis with NASH related cirrhosis. Only two miRNAs (miR-4725 and miR-150) are commonly upregulated in both conditions, and one miRNA is commonly downregulated (miR-3162).

Article Snippet: MiR-10a , PI3K/AKT/mTOR , HCC patients, human HCC cell lines (Huh7, HepG2, and PLC) , Cell proliferation inhibition chemosensibility , Musashi 1 (MSI1) , [ ] .

Techniques: Gene Expression, Control, Over Expression

Journal: Cancers

Article Title: MiRNAs in Alcohol-Related Liver Diseases and Hepatocellular Carcinoma: A Step toward New Therapeutic Approaches?

doi: 10.3390/cancers15235557

Figure Lengend Snippet: Summary of deregulated miRNAs and their impacts on different pathways associated with HCC.

Article Snippet: MiR-10a , PI3K/AKT/mTOR , HCC patients, human HCC cell lines (Huh7, HepG2, and PLC) , Cell proliferation inhibition chemosensibility , Musashi 1 (MSI1) , [ ] .

Techniques: Inhibition, Cell Differentiation, Migration, Histone Deacetylase Assay, Blocking Assay

Journal: Cancers

Article Title: MiRNAs in Alcohol-Related Liver Diseases and Hepatocellular Carcinoma: A Step toward New Therapeutic Approaches?

doi: 10.3390/cancers15235557

Figure Lengend Snippet: ( A ) A transcriptomic dataset (GSE10694) was used to identify new miRNAs deregulated in hepatocellular carcinoma with alcohol abuse. The data are represented in a heatmap showing the log2 fold change of deregulated miRNAs. ( B ) Significantly deregulated microRNAs were subjected to literature-based screening to classify them in the most common HCC-related pathways. The data were retrieved in July 2023. miRNAs in red bubbles: upregulated; miRNA in blue bubbles: downregulated. Black arrows: activation of the pathway; Blue inhibitory arrows: pathway inhibition. Created with Biorender.com .

Article Snippet: MiR-10a , PI3K/AKT/mTOR , HCC patients, human HCC cell lines (Huh7, HepG2, and PLC) , Cell proliferation inhibition chemosensibility , Musashi 1 (MSI1) , [ ] .

Techniques: Activation Assay, Inhibition

Journal: The Journal of International Medical Research

Article Title: The combination of ulinastatin and 5-fluorouracil synergistically inhibits hepatocellular carcinoma growth

doi: 10.1177/0300060520909776

Figure Lengend Snippet: 5-FU-resistant HCC cells exhibited increased stemness compared with parental cells. (a and b) The IC 50 values of 5-FU in Huh7-FT and Huh7 cells. (c and d) Sphere-formation ability of Huh7-FT and Huh7 cells. (e) ALDH1 activity was determined in Huh7 and Huh7-FT cells. (f and g) The expression of stemness regulators were measured in Huh7 and Huh7-FT cells. *P<0.01. 5-FU, 5-fluorouracil; HCC, hepatocellular carcinoma; ALDH1, aldehyde dehydrogenase.

Article Snippet: The HCC cell line Huh7 was purchased from Sino Biological (Beijing, China) and cultured in DMEM (Thermo Fisher Scientific, Waltham, MA, USA) with 15% fetal bovine serum (FBS; Sciencell, Carlsbad, CA, USA) at 37°C in 5% CO 2 .

Techniques: Activity Assay, Expressing

Journal: The Journal of International Medical Research

Article Title: The combination of ulinastatin and 5-fluorouracil synergistically inhibits hepatocellular carcinoma growth

doi: 10.1177/0300060520909776

Figure Lengend Snippet: UTI attenuated the stemness of 5-FU-resistant HCC cells. (a and b) Sphere-formation ability was evaluated in Huh7-FT cells treated with different concentrations of UTI. (c) ALDH1 activity was measured in Huh7-FT cells treated with different concentrations of UTI. (d and e) The expression of stemness regulators was detected in Huh7-FT cells treated with different concentrations of UTI. (f and g) Cell viability was examined in the cells described in (a). *P<0.05, **P<0.01. UTI, ulinastatin; 5-FU, 5-fluorouracil; HCC, hepatocellular carcinoma; ALDH1, aldehyde dehydrogenase.

Article Snippet: The HCC cell line Huh7 was purchased from Sino Biological (Beijing, China) and cultured in DMEM (Thermo Fisher Scientific, Waltham, MA, USA) with 15% fetal bovine serum (FBS; Sciencell, Carlsbad, CA, USA) at 37°C in 5% CO 2 .

Techniques: Activity Assay, Expressing

Journal: The Journal of International Medical Research

Article Title: The combination of ulinastatin and 5-fluorouracil synergistically inhibits hepatocellular carcinoma growth

doi: 10.1177/0300060520909776

Figure Lengend Snippet: UTI attenuated the 5-FU resistance of 5-FU-resistant HCC cells. (a and b) Cell viability was determined in Huh7 and Huh7-FT cells treated with 5-FU with and without UTI. (c and d) Levels of the apoptotic executors cleaved caspase 3 and cleaved PARP were examined in the cells described in (a). **P<0.01. UTI, ulinastatin; 5-FU, 5-fluorouracil; HCC, hepatocellular carcinoma.

Article Snippet: The HCC cell line Huh7 was purchased from Sino Biological (Beijing, China) and cultured in DMEM (Thermo Fisher Scientific, Waltham, MA, USA) with 15% fetal bovine serum (FBS; Sciencell, Carlsbad, CA, USA) at 37°C in 5% CO 2 .

Techniques:

Journal: The Journal of International Medical Research

Article Title: The combination of ulinastatin and 5-fluorouracil synergistically inhibits hepatocellular carcinoma growth

doi: 10.1177/0300060520909776

Figure Lengend Snippet: UTI suppressed Wnt/β-catenin signaling in 5-FU-FT cells. (a and b) Wnt3a and β-catenin expression were detected in Huh7-FT cells treated with different concentrations of UTI. (c and d) The expression of downstream β-catenin effectors were examined in Huh7-FT cells treated with different concentrations of UTI. **P<0.01. UTI, ulinastatin; 5-FU, 5-fluorouracil.

Article Snippet: The HCC cell line Huh7 was purchased from Sino Biological (Beijing, China) and cultured in DMEM (Thermo Fisher Scientific, Waltham, MA, USA) with 15% fetal bovine serum (FBS; Sciencell, Carlsbad, CA, USA) at 37°C in 5% CO 2 .

Techniques: Expressing

Journal: The Journal of International Medical Research

Article Title: The combination of ulinastatin and 5-fluorouracil synergistically inhibits hepatocellular carcinoma growth

doi: 10.1177/0300060520909776

Figure Lengend Snippet: UTI attenuated the stemness and 5-FU resistance of 5-FU-resistant HCC cells by modulating Wnt/β-catenin signaling. (a and b) Sphere-formation ability was evaluated in Huh7-FT cells treated with UTI with and without SKL2001. (c) ALDH1 activity was measured in Huh7-FT cells treated with UTI with and without SKL2001. (d and e) The expression of stemness regulators were examined in Huh7-FT cells treated with UTI with and without SKL2001. (f and g) The viability of Huh7 and Huh7-FT cells treated with 5-FU and UTI with and without SKL2001. **P<0.01. UTI, ulinastatin; 5-FU, 5-fluorouracil; HCC, hepatocellular carcinoma; ALDH1, aldehyde dehydrogenase.

Article Snippet: The HCC cell line Huh7 was purchased from Sino Biological (Beijing, China) and cultured in DMEM (Thermo Fisher Scientific, Waltham, MA, USA) with 15% fetal bovine serum (FBS; Sciencell, Carlsbad, CA, USA) at 37°C in 5% CO 2 .

Techniques: Activity Assay, Expressing